The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Macrolide antibiotics for cystic fibrosis
Open accessAbstract
BACKGROUND: Macrolide antibiotics may have a modifying role in diseases which involve airway infection and inflammation, like cystic fibrosis. OBJECTIVES: To test the hypotheses that, in people with cystic fibrosis, macrolide antibiotics: 1. improve clinical status compared to placebo or another antibiotic; 2. do not have unacceptable adverse effects. If benefit was demonstrated, we aimed to assess the optimal type, dose and duration of macrolide therapy. SEARCH METHODS: We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register comprising references identified from comprehensive electronic database searches, handsearching relevant journals and abstract books of conference proceedings.We contacted investigators known to work in the field, previous authors and pharmaceutical companies manufacturing macrolide antibiotics for unpublished or follow-up data (May 2010).Latest search of the Group's Cystic Fibrosis Trials Register: 29 February 2012. SELECTION CRITERIA: Randomised controlled trials of macrolide antibiotics compared to: placebo; another class of antibiotic; another macrolide antibiotic; or the same macrolide antibiotic at a different dose. DATA COLLECTION AND ANALYSIS: Two authors independently extracted data and assessed risk of bias. Seven groups were contacted and provided additional data which were incorporated into the review. MAIN RESULTS: Ten of 31 studies identified were included (959 patients). Five studies with a low risk of bias examined azithromycin versus placebo and demonstrated consistent improvement in forced expiratory volume in one second over six months (mean difference at six months 3.97% (95% confidence interval 1.74% to 6.19%; n = 549, from four studies)). Patients treated with azithromycin were approximately twice as likely to be free of pulmonary exacerbation at six months, odds ratio 1.96 (95% confidence interval 1.15 to 3.33). With respect to secondary outcomes, there was a significant reduction in need for oral antibiotics and greater weight gain in those taking azithromycin. Adverse events were uncommon and not obviously associated with azithromycin, although a once-weekly high dose regimen was associated with more frequent gastrointestinal adverse events. Treatment with azithromycin was associated with reduced identification of Staphylococcus aureus on respiratory culture, but also a significant increase in macrolide resistance. AUTHORS' CONCLUSIONS: This review provides evidence of improved respiratory function after six months of azithromycin. Data beyond six months were less clear, although reduction in pulmonary exacerbation was sustained. Treatment appeared safe over a six-month period; however, emergence of macrolide resistance was a concern. A multi-centre trial examining long-term effects of this antibiotic treatment is needed, especially for infants recognised through newborn screening.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA
Riordan, J. R., Rommens, J. M., Kerem, B.-S., Alon, N., Rozmahel, R., Grzelczak, Z., Zielenski, J., Lok, S., Plavsic, N., Chou, J.-L., et al. (1989) · Science · doi:10.1126/science.2475911 · Cited by 7,418
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634
Assessing Risk of Bias in Included Studies
Higgins, J. P., & Altman, D. G. (2008) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9780470712184.ch8 · Cited by 3,396
Nährlich, L., Mainz, J. G., Adams, C., Engel, C., Herrmann, G., Icheva, V., Lauer, J., Deppisch, C., Wirth, A., Unger, K., et al. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350071 · Cited by 2,525
Matsui, H., Grubb, B. R., Tarran, R., Randell, S. H., Gatzy, J. T., Davis, C. W., & Boucher, R. C. (1998) · Cell · doi:10.1016/s0092-8674(00)81724-9 · Cited by 1,169
Saiman, L., Marshall, B. C., Mayer-Hamblett, N., Burns, J. L., Quittner, A. L., Cibene, D. A., Coquillette, S., Fieberg, A. Y., Accurso, F. J., Campbell III, P. W., et al. (2003) · JAMA · doi:10.1001/jama.290.13.1749 · Cited by 958
Equi, A., Balfour-Lynn, I., Bush, A., & Rosenthal, M. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11081-6 · Cited by 543
Wolter, J. (2002) · Thorax · doi:10.1136/thorax.57.3.212 · Cited by 518
Retsema, J., Girard, A., Schelkly, W., Manousos, M., Anderson, M., Bright, G., Borovoy, R., Brennan, L., & Mason, R. (1987) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.31.12.1939 · Cited by 464
Clement, A. (2006) · Thorax · doi:10.1136/thx.2005.057950 · Cited by 292
Long-term azithromycin may improve lung function in children with cystic fibrosis
Jaffé, A., Francis, J., Rosenthal, M., & Bush, A. (1998) · The Lancet · doi:10.1016/s0140-6736(05)78360-4 · Cited by 276
Aaron, S. D., Vandemheen, K. L., Ferris, W., Fergusson, D., Tullis, E., Haase, D., Berthiaume, Y., Brown, N., Wilcox, P., Yozghatlian, V., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67060-2 · Cited by 240
Anti-inflammatory activity of macrolides: a new therapeutic potential?
Labro, M. T. (1998) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/41.suppl_2.37 · Cited by 230
Meta‐analysis combining parallel and cross‐over clinical trials. I: Continuous outcomes
Curtin, F., Altman, D. G., & Elbourne, D. (2002) · Statistics in Medicine · doi:10.1002/sim.1205 · Cited by 207
Molecular insights into the physiology of the ‘thin film’ of airway surface liquid
Boucher, R. C. (1999) · The Journal of Physiology · doi:10.1111/j.1469-7793.1999.0631u.x · Cited by 173
The Influence of Azithromycin on the Biofilm Formation of Pseudomonas aeruginosa in vitro
Ichimiya, T., Takeoka, K., Hiramatsu, K., Hirai, K., Yamasaki, T., & Nasu, M. (2009) · Chemotherapy · doi:10.1159/000239440 · Cited by 156
Meta‐analysis combining parallel and cross‐over clinical trials. II: Binary outcomes
Curtin, F., Elbourne, D. R., & Altman, D. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1206 · Cited by 127
Meta‐analysis combining parallel and cross‐over clinical trials. III: The issue of carry‐over
Curtin, F., Elbourne, D. R., & Altman, D. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1207 · Cited by 123
Ratjen, F. A., Saiman, L. M., Mayer-Hamblett, N., Lands, L. C., Kloster, M., Thompson, V., Emmett, P., Marshall, B. C., Accurso, F. J., Sagel, S. D., et al. (2012) · CHEST Journal · doi:10.1378/chest.12-0628 · Cited by 123
Diffuse panbronchiolitis and cystic fibrosis: East meets West.
Høiby, N. (1994) · Thorax · doi:10.1136/thx.49.6.531 · Cited by 121
Pathogenicity of microbes associated with cystic fibrosis
Hutchison, M. L., & Govan, J. R. W. (1999) · Microbes and Infection · doi:10.1016/s1286-4579(99)80518-8 · Cited by 116
Tramper‐Stranders, G. A., Wolfs, T. F. W., Fleer, A., Kimpen, J. L. L., & van der Ent, C. K. (2006) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000247109.44249.ac · Cited by 110
Phaff, S. J., Tiddens, H. A. W. M., Verbrugh, H. A., & Ott, A. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl014 · Cited by 102
Prophylactic anti-staphylococcal antibiotics for cystic fibrosis
Smyth, A. R., & Walters, S. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001912 · Cited by 100
Macrolide antibiotics for cystic fibrosis
Southern, K. W., Barker, P., Solís-Moya, A., & Patel, L. B. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002203.pub3 · Cited by 98
Self-citationProphylactic anti-staphylococcal antibiotics for cystic fibrosis
Smyth, A. R., & Rosenfeld, M. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001912.pub4 · Cited by 91
Effect of Clarithromycin on Lymphocytes in Chronic Respiratory Pseudomonas Aeruginosa Infection
Yanagihara, K., Tomono, K., Sawai, T., Hirakata, Y., Kadota, J., Koga, H., Tashiro, T., & KOHNO, S. (1997) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.155.1.9001333 · Cited by 87
Ordoñez, C. L., Stulbarg, M. S., Grundland, H., Liu, J. T., & Boushey, H. A. (2001) · Pediatric Pulmonology · doi:10.1002/ppul.1085 · Cited by 81
Heterogeneity of Treatment Response to Azithromycin in Patients with Cystic Fibrosis
Saiman, L. M., Mayer-Hamblett, N., Campbell, P. W., & Marshall, B. C. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200502-218oc · Cited by 76
Macrolide antibiotics for cystic fibrosis
Southern, K. W., Barker, P., Solís-Moya, A., & Patel, L. B. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002203.pub2 · Cited by 70
Self-citationEffects of prolonged use of azithromycin in patients with cystic fibrosis: A meta-analysis
Florescu, D. F., Murphy, P. J., & Kalil, A. C. (2009) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2009.03.002 · Cited by 63
Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection
Steinkamp, G., Schmitt‐Grohé, S., Döring, G., Staab, D., Pfründer, D., Beck, G., Schubert, R., & Zielen, S. (2008) · Respiratory Medicine · doi:10.1016/j.rmed.2008.03.009 · Cited by 59
Beringer, P. M., Huynh, K. M. T., Kriengkauykiat, J., Bi, L., Hoem, N., Louie, S. G., Han, E. E., Nguyen, T., Hsu, D. I., Rao, P. A., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.12.5013-5017.2005 · Cited by 57
Dailyversusweekly azithromycin in cystic fibrosis patients
McCormack, J. G., Bell, S. C., Senini, S., Walmsley, K., Patel, K., Wainwright, C. E., Serisier, D. J., Harris, M., & Bowler, S. (2007) · European Respiratory Journal · doi:10.1183/09031936.00163306 · Cited by 55
Hansen, C. R., Pressler, T., Høiby, N., & Johansen, H. K. (2008) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2008.09.001 · Cited by 50
Kabra, S. K., Pawaiya, R., Lodha, R., Kapil, A., Kabra, M., Vani, A. S., Agarwal, G., & Shastri, S. S. (2009) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2009.09.001 · Cited by 40
Effect of Macrolides on In Vivo Ion Transport across Cystic Fibrosis Nasal Epithelium
Barker, P., Gillie, D. J., Schechter, M. S., & Rubin, B. K. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200311-1508oc · Cited by 33
Self-citationProphylactic anti-staphylococcal antibiotics for cystic fibrosis
Smyth, A. R., & Walters, S. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001912.pub2 · Cited by 27
Macrolide antibiotics for cystic fibrosis
Southern, K., Barker, P., & Solis, A. (2003) · doi:10.1002/14651858.cd002203 · Cited by 21
Self-citationSteinkamp, G., Schmitt‐Grohé, S., Döring, G., Worlitzsch, D., Staab, D., Schubert, R., & Zielen, S. (2006) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(06)80098-6 · Cited by 12
Cited by
Cystic Fibrosis Pulmonary Guidelines: Chronic Medications for Maintenance of Lung Health
Flume, P. A., O'Sullivan, B. P., Robinson, K. A., Goss, C. H., Mogayzel, P. J., Willey-Courand, D. B., Bujan, J., Finder, J., Lester, M., Quittell, L., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200705-664oc · Cited by 1,024
ECFS best practice guidelines: the 2018 revision
Castellani, C., Duff, A. J. A., Bell, S. C., Heijerman, H. G. M., Munck, A., Ratjen, F., Sermet-Gaudelus, I., Southern, K. W., Barben, J., Flume, P. A., et al. (2018) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2018.02.006 · Cited by 765
Self-citationMechanisms of Action and Clinical Application of Macrolides as Immunomodulatory Medications
Kanoh, S., & Rubin, B. K. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00078-09 · Cited by 708
Azithromycin: Mechanisms of action and their relevance for clinical applications
Parnham, M. J., Haber, V. E., Giamarellos-Bourboulis, E. J., Perletti, G., Verleden, G. M., & Vos, R. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.03.003 · Cited by 661
European cystic fibrosis society standards of care: best practice guidelines
Smyth, A. R., Bell, S. C., Bojcin, S., Bryon, M., Duff, A., Flume, P., Kashirskaya, N., Munck, A., Ratjen, F., Schwarzenberg, S. J., et al. (2014) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2014.03.010 · Cited by 582
Self-citation
Metadata
- Authors
- Southern, K. W., Barker, P. M., Solis-Moya, A., & Patel, L.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2012-11-14
- Volume
- 11
- Pages
- CD002203-CD002203
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2148645653
- Cited by
- 298
- References
- 42
- FWCI
- 20.16
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.